Alexander N Slade1, Michael R Waters2, Nicholas A Serrano3. 1. Department of Radiation Oncology, Virginia Commonwealth University Health System, Massey Cancer Center, Box 980058, Richmond, VA, 23298, USA. alexander.n.slade@vcuhealth.org. 2. Department of Radiation Oncology, Virginia Commonwealth University Health System, Massey Cancer Center, Box 980058, Richmond, VA, 23298, USA. 3. Overlake Medical Center, Radiation Oncology, Bellevue, WA, USA.
Abstract
PURPOSE: Insomnia and related sleep disorders are common complaints among cancer patients, and use of prescription sleep aids can be high in the treatment setting. The prevalence of sleep disturbance and prescription sleep aid use in the community-dwelling cancer survivorship population, however, remains relatively unexplored. We aim to ascertain the extent to which a cancer diagnosis is associated with sleep disturbances and prescription sleep aid use as measured in several cross sections of individuals across multiple disease sites and time since cancer diagnosis. METHODS: We used data from five cross-sectional cycles of the National Health and Nutrition Evaluation Survey (NHANES) from 2005 to 2014. We identified a total of 2371 individuals who reported a diagnosis of cancer (averaging 61 years old) and 25,788 individuals who did not report a cancer diagnosis (averaging 45 years old). We considered several patient-reported sleep-related outcomes. Multivariate regression analyses, as well as propensity score matching, were used to clarify the relationship between sleep disturbances, prescription sleep aid use, and cancer diagnosis, stratified by time since diagnosis and primary disease site. RESULTS: Reported sleep disturbance was common in cancer survivors, with approximately 34% of patients with a history of cancer reporting having ever been told they had trouble sleeping, compared to 23% of non-cancer patients in the general population with no history of cancer (p < 0.001). Propensity score matching supported a significantly higher rate of trouble sleeping among cancer survivors compared to matched controls. Compared to the general adult population without cancer, cancer survivors 11 or more years past diagnosis were more likely to report being diagnosed with trouble sleeping or a sleep disorder. Further, patients with gynecological cancers were more likely to report prescription sleep aid use, sleep disorders, and trouble sleeping compared to adults without a history of cancer. CONCLUSIONS: Sleeping problems are common in the cancer survivorship population, especially in patients with a long survivorship history and a history of gynecological cancers. Consideration of symptoms of insomnia and sleep disturbance may be helpful in the follow-up care of these patients.
PURPOSE:Insomnia and related sleep disorders are common complaints among cancerpatients, and use of prescription sleep aids can be high in the treatment setting. The prevalence of sleep disturbance and prescription sleep aid use in the community-dwelling cancer survivorship population, however, remains relatively unexplored. We aim to ascertain the extent to which a cancer diagnosis is associated with sleep disturbances and prescription sleep aid use as measured in several cross sections of individuals across multiple disease sites and time since cancer diagnosis. METHODS: We used data from five cross-sectional cycles of the National Health and Nutrition Evaluation Survey (NHANES) from 2005 to 2014. We identified a total of 2371 individuals who reported a diagnosis of cancer (averaging 61 years old) and 25,788 individuals who did not report a cancer diagnosis (averaging 45 years old). We considered several patient-reported sleep-related outcomes. Multivariate regression analyses, as well as propensity score matching, were used to clarify the relationship between sleep disturbances, prescription sleep aid use, and cancer diagnosis, stratified by time since diagnosis and primary disease site. RESULTS: Reported sleep disturbance was common in cancer survivors, with approximately 34% of patients with a history of cancer reporting having ever been told they had trouble sleeping, compared to 23% of non-cancerpatients in the general population with no history of cancer (p < 0.001). Propensity score matching supported a significantly higher rate of trouble sleeping among cancer survivors compared to matched controls. Compared to the general adult population without cancer, cancer survivors 11 or more years past diagnosis were more likely to report being diagnosed with trouble sleeping or a sleep disorder. Further, patients with gynecological cancers were more likely to report prescription sleep aid use, sleep disorders, and trouble sleeping compared to adults without a history of cancer. CONCLUSIONS: Sleeping problems are common in the cancer survivorship population, especially in patients with a long survivorship history and a history of gynecological cancers. Consideration of symptoms of insomnia and sleep disturbance may be helpful in the follow-up care of these patients.
Entities:
Keywords:
Cancer survivorship; NHANES; Prescription sleep aid; Sleep disturbance
Authors: Shannon N Westin; Charlotte C Sun; Celestine S Tung; Robin A Lacour; Larissa A Meyer; Diana L Urbauer; Michael M Frumovitz; Karen H Lu; Diane C Bodurka Journal: J Cancer Surviv Date: 2015-08-06 Impact factor: 4.442
Authors: Margaret M Lubas; Mariana Szklo-Coxe; Belinda N Mandrell; Carrie R Howell; Kirsten K Ness; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Kevin R Krull; Tara M Brinkman Journal: Support Care Cancer Date: 2021-08-26 Impact factor: 3.603
Authors: Lee Ingle; Samantha Ruilova; Yunsung Cui; Vanessa DeClercq; Ellen Sweeney; Zhijie Michael Yu; Cynthia C Forbes Journal: Cancer Causes Control Date: 2022-06-14 Impact factor: 2.532